Boston Scientific (BSX) said Monday it agreed to acquire medical device company SoniVie.
Boston Scientific currently owns an equity stake of around 10 percent in SoniVie. The transaction consists of an upfront payment of $360 million for the remaining 90% stake and up to $180 million upon achievement of a regulatory milestone.
SoniVie's main product is the Tivus intravascular ultrasound system, an investigational technology designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation for hypertension. The Tivus system is designed to help reduce activity in the kidney's renal nerves and serve as an alternative or adjunctive therapy to medications to help regulate blood pressure.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.